What do Theranos, 23andMe, and Zenefits have in common? These well-hyped companies failed to meet regulatory requirements.
In 2013, 23andMe got slapped by federal regulators for failing to respond to emails. In 2015, the much-hyped biotech startup Theranos was cited by the feds for serious deficiencies that put patient safety in “immediate jeopardy.” And last week, Zenefits, a company that claimed to demystify compliance, announced that its CEO would resign for, you guessed it, problems with compliance.
